CJC-1295 & Ipamorelin

GHRH and Ghrelin: Two Separate Pathways

UKPWritten & reviewed by The UK Peptides Editorial Team · Research library, UK Peptides1 min readLast reviewed 2026-08-233 cited sources

The short answer

GHRH from the hypothalamus and ghrelin from the stomach act at different receptors on pituitary somatotrophs, both promoting growth hormone release. Somatostatin opposes both. The existence of two stimulatory inputs is why compounds targeting each are studied together.

Key facts

GHRH origin
Hypothalamus
GHRH receptor
GHRHR
Ghrelin origin
Stomach
Ghrelin receptor
GHS-R1a
Common target
Pituitary somatotrophs
Opposing signal
Somatostatin

Two stimulatory inputs, one inhibitory

GH release is governed by at least three signals. GHRH stimulates it, ghrelin stimulates it through a separate receptor, and somatostatin inhibits it. Net output reflects the balance, which is why a compound acting on one input does not fully control the result. Somatostatin tone still matters.

Why two stimulatory pathways exist

They carry different information. GHRH is hypothalamic and integrates central signals; ghrelin is gastric and rises with fasting, linking GH release to nutritional state. Two inputs let the pituitary respond to distinct physiological circumstances rather than a single signal.

Research material referenced

CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested

Buy CJC-1295 + Ipamorelin · £36.99

The receptors are distinct

GHRHR and GHS-R1a are different G-protein-coupled receptors with different endogenous ligands and different signalling. This is not two names for one target, a GHRH analogue and a ghrelin receptor agonist act at separate proteins, which is why their combination has a mechanistic rationale that combinations elsewhere in this library lack.

Where somatostatin complicates things

Somatostatin inhibition is often the limiting factor. During a somatostatin peak, stimulating either receptor produces less than the same stimulus would during a trough. This is a real reason why timing matters in GH secretagogue research and why results can vary with when a stimulus is applied.

What this predicts about combination

Two independent stimulatory inputs converging on one cell type is a textbook setting for additive or synergistic effects. It is also, as with every combination question, a rationale rather than a result. Establishing additivity requires testing each agent alone and together in the same experiment.

Frequently asked questions

Are GHRH and ghrelin the same pathway?
No. Different hormones, different origins, different receptors, both acting on pituitary somatotrophs.
Why does the body have two stimulatory inputs?
They carry different information. GHRH integrates central signals; ghrelin links GH release to nutritional state.
What limits GH release?
Somatostatin, which opposes both stimulatory pathways. Net output reflects the balance.

Extended research context

The CJC-1295 & Ipamorelin deep dive

Deep dive: why CJC-1295 and Ipamorelin are studied together

CJC-1295 is a modified GHRH (growth-hormone-releasing hormone) analogue; Ipamorelin is a selective growth-hormone secretagogue that binds the ghrelin receptor (GHS-R1a). In pituitary-cell research models the two act on independent pathways whose downstream effect converges on GH release. CJC-1295 amplifies the endogenous GHRH signal while Ipamorelin adds a separate ghrelin-pathway stimulus. That's why supplier catalogues frequently package them together as a research reference blend.

DAC vs no-DAC: which CJC-1295 is which

'CJC-1295 with DAC' contains a Drug Affinity Complex (a Lys-maleimide moiety) that binds serum albumin and extends half-life to several days. 'CJC-1295 no-DAC' (also called Modified GRF 1-29) lacks the linker and clears in minutes. These are pharmacologically different peptides. A CoA must specify which form is in the vial; mass differs (~3,367 Da with DAC vs ~3,367 minus linker for no-DAC).

Ipamorelin's selectivity profile

Unlike earlier GHS-R agonists (e.g. GHRP-6), Ipamorelin was engineered for minimal cross-activity at cortisol- and prolactin-releasing pathways in research models. That receptor selectivity is why it is the reference secretagogue for controlled pituitary-cell studies.

Research applications

  • ▸Pituitary-cell GH-release assays (comparator vs GHRH and hexarelin)
  • ▸Half-life comparison studies: DAC vs no-DAC CJC-1295 forms
  • ▸Ghrelin-receptor binding assays for Ipamorelin analogue development
  • ▸Analytical HPLC method development for lipidated GHRH analogues
  • ▸Stability testing under refrigerated storage

Handling checklist

  • ✓Store lyophilised at −20 °C long-term
  • ✓Reconstitute in bacteriostatic water; both peptides dissolve readily
  • ✓Aliquot immediately, refrigerate at 2–8 °C, use within 28 days
  • ✓Confirm salt form and DAC/no-DAC status on CoA before starting a study
  • ✓Do not use for human administration (research reference only)

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing DAC and no-DAC CJC-1295

Fix: Check the CoA. The two have very different pharmacokinetics.

✗ Assuming Ipamorelin acts on GHRH receptors

Fix: It binds the ghrelin receptor (GHS-R1a), a separate pathway from CJC-1295.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate 2–8 °C after reconstitution.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Related questions researchers ask

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this contentReport a factual error in this article

More CJC-1295 & Ipamorelin articles

Popular across the research hub

One flagship guide from every other research category.

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.

← Back to Forum